Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer

Bayer has announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.S., Japan and Europe, for the second line treatment of…
Read the full story: Breaking World Pharma News